Kidney Cancer
FY23 Ad Hoc Programmatic Reviewers:
Michael Serzan, M.D.
Dana-Farber Cancer Institute
Last updated Thursday, July 16, 2026
Michael Serzan, M.D.
Dana-Farber Cancer Institute
Last updated Thursday, July 16, 2026